Integer Holdings Corporation reported a modest increase in revenue for the first quarter of 2026, generating $439.6 million, up from $437.4 million in the same period last year. The company achieved a net income of $16.5 million, or $0.48 per diluted share, a significant turnaround from a loss of $22.5 million, or $(0.66) per diluted share, in the first quarter of 2025. This improvement in profitability was attributed to higher sales in the Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation segments, despite a decline in the Other Markets category.
The company's gross profit decreased to $109.6 million, down from $120.3 million year-over-year, primarily due to lower fixed cost absorption linked to reduced production volumes. Operating expenses rose to $77.7 million, an increase of 9.8% compared to the previous year, driven by higher selling, general, and administrative (SG&A) costs, as well as research and development expenses. However, the operating margin fell to 7.2% from 11.3% in the prior year, reflecting the challenges in maintaining profitability amid rising costs.
Integer has been active in strategic acquisitions, having completed several transactions to enhance its capabilities. Notably, the company acquired Biocoat, VSi, and Precision in 2025, which are expected to contribute to its growth in the medical device sector. The company is also undergoing a strategic review to explore options for maximizing shareholder value, including potential mergers or sales, although no definitive timeline has been established for this process.
Operationally, Integer's cash and cash equivalents decreased to $8.1 million as of April 3, 2026, down from $17.2 million at the end of 2025. The company reported a current ratio of 3.75, indicating a strong liquidity position. Integer's total liabilities increased to $1.7 billion, with long-term debt rising to $1.25 billion. The company maintains a robust borrowing capacity of approximately $729.7 million under its revolving credit facility, which it plans to utilize for ongoing operational needs and potential future investments.
Looking ahead, Integer anticipates that sales growth may be impacted by lower adoption rates for three new products. The company remains focused on aligning its cost structure with market conditions and is committed to enhancing its operational efficiencies. Despite the challenges, Integer's management believes that its current cash flows and available credit will be sufficient to meet its working capital and capital expenditure requirements over the next twelve months.
About Integer Holdings Corp
Integer Holdings Corporation is a leading medical device contract manufacturer specializing in cardiac rhythm management, neuromodulation, and vascular markets. It develops and produces innovative components, sub-assemblies, and finished devices for OEMs worldwide. The company emphasizes high-quality, regulatory-compliant solutions, leveraging advanced technologies and strategic acquisitions to serve large healthcare providers and medical device companies in growth-oriented segments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.